NCT06478563View on ClinicalTrials.gov

A Research Study Looking at Different Oral Formulations and the Effect of Food Intake on How the Medicine NNC0487-0111 Behaves in the Body of Participants Living With Overweight or Obesity

PHASE1CompletedINTERVENTIONAL
Enrollment

133

Participants

Timeline

Start Date

June 27, 2024

Primary Completion Date

June 5, 2025

Study Completion Date

July 1, 2025

Conditions
ObesityOverweight
Interventions
DRUG

NNC0487-0111 (formulation D)

Participants will receive NNC0487-0111 (formulation D) tablet once daily.

DRUG

NNC0487-0111 (formulation C)

Participants will receive NNC0487-0111 (formulation C) tablet once daily.

Trial Locations (1)

68502

Celerion, Lincoln, Lincoln

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT06478563 - A Research Study Looking at Different Oral Formulations and the Effect of Food Intake on How the Medicine NNC0487-0111 Behaves in the Body of Participants Living With Overweight or Obesity | Biotech Hunter | Biotech Hunter